On Demand, On Purpose: Fashion Manufacturing That Doesn’t Cost the Earth
Daily Compliance News: July 16, 2025, The Corruption Comes to Cannes’ Edition
Understanding Human Trafficking and Modern Slavery: A Business Imperative with Clint Palermo
PODCAST: Williams Mullen's Benefits Companion - Navigating Fiduciary Responsibilities in a Tide-Turning ESG Era
ESG Essentials: What You Need To Know Now - Episode 18 - The Reshaping of ESG & DEI
Compliance into the Weeds: More Compliance Challenges in the Trump Era
Podcast — UK FinReg Focus Areas in 2025: Sectoral Trends
Environmental and Sustainability Regulations & the New Administration
Podcast - Beyond Compliance: A Deep Dive into Carbon Markets Fraud and the Government's Response
ESG Essentials: What You Need To Know Now - Episode 17 - The Evolution of ESG Enforcement Under the SEC
Navigating ESG: Preparing for Future Regulations (Part Two) — Regulatory Oversight Podcast
Regulatory Uncertainty: Benefits-Related Legal Challenges in a Post-Chevron World — Troutman Pepper Podcast
Navigating ESG: The Growing Importance and Compliance Challenges (Part One) — Regulatory Oversight Podcast
AGG Talks: Cross-Border Business Podcast - Episode 16: The Political and Legal Maze of ESG in the U.S. and Abroad
Episode 326 -- Dottie Schindlinger on Diligent's Report on Board Oversight of Cybersecurity Risks and Performance
Why ESG Matters?
JONES DAY TALKS®: ESG Reporting Rules: The SEC, CSRD, and California– Who's on the Hook?
ESG Masterclass — Legal Risks Hiding in Your DEIB Programming
Leaning in on AI in Compliance Programs
ESG Masterclass — ESG and Impact Investing
Scimplify, an Indian startup that connects ag and pharmaceutical companies to manufacturers of specialty chemicals, announced that it raised $40 million in its Series B round. Grão Direto, a Brazilian digital trading...more
Our last two alerts in this series covered key considerations for early-stage companies in the alternative protein industry and provided an overview of financing in the alternative protein industry. This alert follows those...more
Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more
After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their...more
Following a record-breaking year for IPOs and other going-public transactions, the beginning of 2022 has presented a challenging environment. That’s largely a result of volatile market conditions due to the ongoing conflict...more
The Rearview Mirror - Robust multiples and fear that the Biden administration might succeed in passing tax laws resulted in 2021 being one of the busiest years ever in the private equity space. Within the capital markets,...more